The NCI60 human tumour cell line anticancer drug screen

被引：2052

作者：

Shoemaker, Robert H. ^{[1
]}

机构：

[1] NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diagnosis, Frederick, MD 21702 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 10期

关键词：

D O I：

10.1038/nrc1951

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The US National Cancer Institute (NCl) 60 human tumour cell line anticancer drug screen (NCl60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.

引用

收藏

页码：813 / 823

页数：11

相关论文

共 93 条

[1] ANTICANCER SPECIFICITY OF SOME ELLIPTICINIUM SALTS AGAINST HUMAN BRAIN-TUMORS IN-VITRO [J].

ACTON, EM ;

NARAYANAN, VL ;

RISBOOD, PA ;

SHOEMAKER, RH ;

VISTICA, DT ;

BOYD, MR .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (14) :2185-2189

[2] Proteasome inhibition in cancer: Development of PS-341 [J].

Adams, J .

SEMINARS IN ONCOLOGY, 2001, 28 (06) :613-619

[3]

Adams J, 1999, CANCER RES, V59, P2615

[4]

ALLEY MC, 1988, CANCER RES, V48, P589

[5] GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].

ALVAREZ, M ;

PAULL, K ;

MONKS, A ;

HOSE, C ;

LEE, JS ;

WEINSTEIN, J ;

GREVER, M ;

BATES, S ;

FOJO, T .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214

[6] Serologic markers to monitor the engraftment, growth, and treatment response of human leukemias in severe combined immunodeficient mice [J].

Arguello, F ;

Sterry, JA ;

Zhao, YZ ;

Alexander, MRA ;

Shoemaker, RH ;

Cohen, HJ .

BLOOD, 1996, 87 (10) :4325-4332

[7] Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts [J].

Arguello, F ;

Alexander, MA ;

Greene, JF ;

Stinson, SF ;

Jorden, JL ;

Smith, EM ;

Kalavar, NT ;

Alvord, WG ;

Klabansky, RL ;

Sausville, EA .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (01) :19-26

[8]

BAI R, 1991, J BIOL CHEM, V266, P15882

[9] Anthrax, MEK and Cancer [J].

Bodart, J. F. ;

Chopra, A. ;

Liang, X. ;

Duesbery, N. .

CELL CYCLE, 2002, 1 (01) :10-15

[10] Alertenone, a dimer of suberosenone from Alertigorgia sp. [J].

Bokesch, HR ;

Blunt, JW ;

Westergaard, CK ;

Cardellina, JH ;

Johnson, TR ;

Michael, JA ;

McKee, TC ;

Hollingshead, MG ;

Boyd, MR .

JOURNAL OF NATURAL PRODUCTS, 1999, 62 (04) :633-635

← 1 2 3 4 5 6 7 8 9 10 →